Key data from the 2023 European Thyroid Association congress: Breakthrough advances in the treatment of Graves’ orbitopathy
Annales d'Endocrinologie · 2024
DOI: 10.1016/j.ando.2024.01.001 ↗Kurz gefasst
Leserbrief in der Zeitschrift Annales d'Endocrinologie, 2024. Verfasst von Miriam Ladsous und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetology and Metabolism, Huriez Hospital, Lille University Hospital, Lille, France. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Graves Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetology and Metabolism, Huriez Hospital, Lille University Hospital, Lille, France.
- Department of Endocrinology and Metabolic diseases, Pôle Cardio-Vasculaire et Métabolique, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex, France. Electronic address: caron.p@chu-toulouse.fr.
Zitieren
APA
Ladsous, M., & Caron, P. (2024). Key data from the 2023 European Thyroid Association congress: Breakthrough advances in the treatment of Graves’ orbitopathy. Annales d'Endocrinologie. https://doi.org/10.1016/j.ando.2024.01.001
Vancouver
Ladsous M, Caron P. Key data from the 2023 European Thyroid Association congress: Breakthrough advances in the treatment of Graves’ orbitopathy. Annales d'Endocrinologie. 2024. doi:10.1016/j.ando.2024.01.001
BibTeX
@article{Ladsous2024,
author = {Ladsous, Miriam and Caron, Philippe},
title = {Key data from the 2023 European Thyroid Association congress: Breakthrough advances in the treatment of Graves’ orbitopathy},
journal = {Annales d'Endocrinologie},
year = {2024},
doi = {10.1016/j.ando.2024.01.001}
}
EUVIMED